Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15054592 | 1.00 | TP53 (0.55) | TP53ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL30410721 | 0.86 | CYP3A4 (0.52) | TP53ALDH1A1MAPTPOLBTDP1 | |
| SCHEMBL29944162 | 0.86 | CYP3A4 (0.65) | TP53ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL232779 | 0.86 | TP53 (0.64) | TP53ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL132541 | 0.86 | CYP3A4 (0.65) | TP53ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL2170079 | 0.85 | CYP3A4 (0.50) | TP53ALDH1A1MAPTKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL3088495 | 0.84 | TP53 (0.62) | TP53ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL9133420 | 0.84 | TP53 (0.62) | TP53ALDH1A1MAPTKDM4EPOLB | |
| Hydrochloric Acid SCHEMBL2299193 | 0.84 | TP53 (0.62) | TP53ALDH1A1MAPTKDM4EPOLB | |
| SCHEMBL8060267 | 0.84 | TP53 (0.62) | TP53ALDH1A1MAPTKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117317401-A | Electrolyte for improving battery performance through biphase stabilization strategy and application thereof | 浙江大学温州研究院 | 2023-12-29 | — | — | CN | claimed |
| CN-114716340-B | Preparation method of iopromide intermediate | 杭州微流汇科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-114716340-A | Preparation method of iopromide intermediate | 杭州微流汇科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-02 | — | — | US | disclosed |
| EP-4663636-A2 | TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BioCryst Pharmaceuticals, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-28 | — | — | US | disclosed |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-08-14 | — | — | US | disclosed |
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2025-06-10 | — | — | US | disclosed |
| CN-119954810-A | Regulator of fused ring derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| WO-2003045913-A1 | BENZAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-05 | — | — | WO | disclosed |
| US-6331640-B1 | TREATMENT OF REPERFUSION INJURIES | HOFFMANN-LA ROCHE INC. | 2001-12-18 | — | — | US | disclosed |
| EP-0408759-A1 | METHOD OF OBTAINING BROMATED AROMATIC AND HETEROCYCLIC COMBINATIONS CONTAINING ACCEPTOR GROUPS | ANDRIEVSKY, Alexandr Mikhailovich (SU) | 1991-01-23 | — | — | EP | disclosed |
| CN-1044808-A | Process for preparing brominated aromatic and heterocyclic compounds containing acceptor groups | ALEXANDR MIKHAILOVICH ANDRIEVS (SU) | 1990-08-22 | — | — | CN | disclosed |
| US-4705861-A | AZO DYE CHEMICAL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-11-10 | — | — | US | disclosed |
| EP-0187231-A2 | Amino phenyl benzothiazoles | BAYER AG (DE) | 1986-07-16 | — | — | EP | disclosed |
| EP-0001246-B1 | PREPARATION OF 2-(3'- OR 4'-AMINOPHENYL)-5(OR 6)-AMINOBENZIMIDAZOLES | CASSELLA Aktiengesellschaft (DE) | 1981-02-25 | — | — | EP | disclosed |
| US-4192947-A | REACTING DIAMINO NITROBENZENE WITH NITROBENZOYL CHLORIDE, CYCLIZING ANILIDE IN AQUEOUS ALKALI, REDUCING NITRO GROUPS WITH SULFIDE | CASSELLA AKTIENGESELLSCHAFT (DE) | 1980-03-11 | — | — | US | disclosed |
| EP-0001246-A1 | Preparation of 2-(3'- or 4'-aminophenyl)-5(or 6)-aminobenzimidazoles | CASSELLA Aktiengesellschaft (DE) | 1979-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270171-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TP53 4560/4885ALDH1A1 1136/4885MAPT 2984/4885 |
| US-12325698-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | TP53 32/4885ALDH1A1 360/4885MAPT 3184/4885 |
| US-20250257040-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TP53 4560/4885ALDH1A1 1136/4885MAPT 2984/4885 |
| US-20260092051-A1 | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME | FLT3, FLT1, ADK | TP53 340/4885ALDH1A1 1637/4885MAPT 3277/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | TP53 4560/4885ALDH1A1 1136/4885MAPT 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.